ProQR Therapeutics (PRQR) Non-Current Deferred Tax Liability (2022 - 2025)
ProQR Therapeutics (PRQR) has disclosed Non-Current Deferred Tax Liability for 4 consecutive years, with $3.0 million as the latest value for Q4 2025.
- Quarterly Non-Current Deferred Tax Liability fell 4.8% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, down 4.8% year-over-year, with the annual reading at $3.0 million for FY2025, 4.8% down from the prior year.
- Non-Current Deferred Tax Liability hit $3.0 million in Q4 2025 for ProQR Therapeutics, down from $3.2 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $4.0 million in Q4 2023 to a low of $3.0 million in Q4 2025.
- Historically, Non-Current Deferred Tax Liability has averaged $3.5 million across 4 years, with a median of $3.5 million in 2022.
- Biggest five-year swings in Non-Current Deferred Tax Liability: grew 5.74% in 2023 and later dropped 21.81% in 2024.
- Year by year, Non-Current Deferred Tax Liability stood at $3.8 million in 2022, then increased by 5.74% to $4.0 million in 2023, then decreased by 21.81% to $3.2 million in 2024, then dropped by 4.8% to $3.0 million in 2025.
- Business Quant data shows Non-Current Deferred Tax Liability for PRQR at $3.0 million in Q4 2025, $3.2 million in Q4 2024, and $4.0 million in Q4 2023.